17336-01-5

Basic information

• Product Name: BENZYLOXYCARBONYL-3-AMINOGLUTARIC ACID
• Synonyms: BENZYLOXYCARBONYL-3-AMINOGLUTARIC ACID;RARECHEM AL CF 0572
• CAS NO: 17336-01-5
• Molecular Formula: C₁₃H₁₅NO₆
• Molecular Weight: 281.26
• Mol File: 17336-01-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZYLOXYCARBONYL-3-AMINOGLUTARIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYLOXYCARBONYL-3-AMINOGLUTARIC ACID(17336-01-5)
• EPA Substance Registry System: BENZYLOXYCARBONYL-3-AMINOGLUTARIC ACID(17336-01-5)

Safety Data

• Hazardous Substances Data: 17336-01-5(Hazardous Substances Data)

Upstream product

• 1948-48-7 3-aminopentanedioic acid 
• 501-53-1 benzyl chloroformate 
• 1724-02-3 glutaconic acid 
• 77856-51-0 dimethyl β-<(benzyloxycarbonyl)amino>glutarate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 17471-98-6 DL-3-Benzyloxycarbonylamino-glutarsaeuremonobenzylester-mono-2.4.5-trichlorphenylester 
• 60833-08-1 (2,6-Dioxo-tetrahydro-pyran-4-yl)-carbamic acid benzyl ester 
• 98577-75-4 {7-[3-Benzyloxycarbonylamino-4-(7-benzyloxycarbonylamino-heptylcarbamoyl)-butyrylamino]-heptyl}-carbamic acid benzyl ester 
• 98577-71-0 {2-(2-Benzyloxycarbonylamino-ethylcarbamoyl)-1-[(2-benzyloxycarbonylamino-ethylcarbamoyl)-methyl]-ethyl}-carbamic acid benzyl ester 
• 98577-73-2 {5-[3-Benzyloxycarbonylamino-4-(5-benzyloxycarbonylamino-pentylcarbamoyl)-butyrylamino]-pentyl}-carbamic acid benzyl ester 
• 98577-74-3 {6-[3-Benzyloxycarbonylamino-4-(6-benzyloxycarbonylamino-hexylcarbamoyl)-butyrylamino]-hexyl}-carbamic acid benzyl ester 
• 98577-72-1 {4-[3-Benzyloxycarbonylamino-4-(4-benzyloxycarbonylamino-butylcarbamoyl)-butyrylamino]-butyl}-carbamic acid benzyl ester 
• 85185-25-7 N,N'-bis<3-<(benzyloxycarbonyl)amino>propyl>-3-pentanediamide 
• 80902-50-7 DL-3-Benzyloxycarbonylamino-glutarsaeuremonobenzylester 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives

A series of amide-linked triacridines of varying interchromophore separation were synthesized as potential DNA trisintercalating agents. The correseponding diamide diacridines (lacking the central chromophore) were also prepared, and the DNA-binding and b